slides · global inventory
Analyze Data
Slide function collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 58,039
Current window 26,551-26,580
Pages 1,935
Rows per page 30
Slide function
26,551-26,580 of 58,039
15
Clinical trial safety data table.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
19
The slide presents clinical trial baseline data for three cohorts.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
20
Clinical trial data visualization (Kaplan-Meier plot).AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
21
Includes a landmark analysis at 9 months for hazard ratios.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
22
Clinical trial data presentation showing PFS, HR, and TTP metrics.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
23
Clinical trial safety data comparing combination therapy vs monotherapy vs standard of care.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
24
The table displays both 'All grades' and 'Grade ≥3' adverse events for specific medical conditions.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations Beat · Satisfaction1 hit
36
The chart displays hazard ratios with 95% confidence intervals for different demographic and clinical categories.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
37
The slide includes a technical explanation of the TAP score methodology using the Ventana PD-L1 (SP263) Assay.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
38
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
40
The plot visualizes subgroup analysis for a clinical trial, indicating treatment efficacy across different patient demographics and clinical characteristics.AstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
41
AstraZeneca | Investor Day Presentation Deck | 42 slidesAstraZeneca | Investor Day Presentation Deck | 42 slides · AstraZeneca
Conference presentation Investor relations 1 hit
05
Includes a highlighted row for RL-007 and a section for equity interests.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
12
Data source: Keefe et al, Schiz Res, 2011.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Problem (Identify pain)Loop · Cost Of Inaction1 hit
18
The chart displays statistical significance markers (*) for specific time points and treatment groups.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
25
The slide includes a time-series line chart showing fEPSP slope over time and a bar chart showing fEPSP amplitude changes across different treatment conditions.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations Beat · Solution (Provide relief)1 hit
29
The slide uses red dashed boxes to highlight the 40mg dose performance in both single and 7-day TID dosing scenarios.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
34
The table uses directional arrows to indicate the direction of change in qEEG endpoints across different cohorts and brain regions (F, C, T, P, O).ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
37
The chart highlights a non-linear dose-response relationship where 40mg appears to be the peak efficacy point across the measured tasks.ATAI | Investor Day Presentation Deck | 42 slides · atai Life Sciences
Conference presentation Investor relations 1 hit
11
Babylon | Investor Conference Presentation Deck | 15 slidesBabylon | Investor Conference Presentation Deck | 15 slides · Babylon
Conference presentation Investor relations 1 hit
12
The slide uses a bar chart to show cost efficiency and a list of metrics to demonstrate scale and AI performance.Babylon | Investor Conference Presentation Deck | 15 slides · Babylon
Conference presentation Investor relations 1 hit
19
The table includes adjustments for impairments, restructuring, share-based compensation, and other non-recurring items.Bausch Health Companies | Investor Conference Presentation Deck | 26 slides · Bausch Health
Conference presentation Investor relations 1 hit
20
The table breaks down cash flow from operations and capital expenditures for Consolidated BHC, Bausch + Lomb, Solta Medical, and Bausch Pharma, leading to a final conversion percentage.Bausch Health Companies | Investor Conference Presentation Deck | 26 slides · Bausch Health
Conference presentation Investor relations 1 hit
21
The slide contains two distinct tables side-by-side representing different reconciliation periods.Bausch Health Companies | Investor Conference Presentation Deck | 26 slides · Bausch Health
Conference presentation Investor relations 1 hit
22
The table provides a standard non-GAAP reconciliation format.Bausch Health Companies | Investor Conference Presentation Deck | 26 slides · Bausch Health
Conference presentation Investor relations 1 hit
15
The slide uses a grouped bar chart structure to compare two different metrics over two years.Berkeley Lights | Investor Conference Presentation Deck | 22 slides · Berkeley Lights
Conference presentation Investor relations Beat · Partnerships1 hit
02
The slide uses stacked bar charts to compare AUM vs Revenue composition.BlackRock | Results Presentation Deck | 14 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
03
Includes LTM organic asset growth rate and LTM organic base fee growth rate metrics.BlackRock | Results Presentation Deck | 14 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
04
The slide uses a combination of bar charts for absolute values and line charts for percentages/per-share metrics.BlackRock | Results Presentation Deck | 14 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit
05
Includes a specific note regarding a $1.1 billion repurchase from PNC in Q2 2020.BlackRock | Results Presentation Deck | 14 slides · BlackRock
Conference presentation Investor relations Beat · What Is1 hit